Resignation of Doron Turjeman from XTL Biopharmaceuticals Ltd. Board of Directors

On October 21, 2025, Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. due to personal reasons. His resignation was not the result of any disagreement with the Company or its management. Noam Band, the Company's Chief Executive Officer, was appointed to serve as a member of the Board of Directors in his place, effective immediately. XTL Biopharmaceuticals Ltd. is an IP portfolio company that holds 100% of the share capital of The Social Proxy Ltd., a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease (SLE). The company is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).